Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Active not recruiting 3Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Sexual Dysfunctions, Psychological 1Breast Neoplasms 1

Interventions

Specimen Handling 81Bevacizumab 66Drug Therapy 64Cisplatin 63Magnetic Resonance Spectroscopy 61Carboplatin 60Gemcitabine 57Radiotherapy 55Cyclophosphamide 55pembrolizumab 52Oxaliplatin 50Capecitabine 50toripalimab 42Paclitaxel 41tislelizumab 40Standard of Care 40Biopsy 38fludarabine 36Fluorouracil 36venetoclax 32Blood Specimen Collection 31Irinotecan 30Injections 30Immune Checkpoint Inhibitors 30anlotinib 29Nivolumab 29Docetaxel 29Surgical Procedures, Operative 28Leucovorin 27Dexamethasone 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Bupropion × 1 year × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡